Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis
NCT03781310Phase 4Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Disease flare rate at 20 weeks and Drop-out rate at 20 weeks. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03781310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781310.